Rekha Hemrajani is an experienced strategic leader helping biotech companies with corporate strategy and corporate finance, as well as building product pipelines through corporate development (both buy side and sell side). She is a strong team builder with extensive senior management experience within public and private biotechnology and pharma companies, investment funds and bulge bracket investment banks.
Recently, as CFO & COO of Arcus Biosciences, a publicly-traded clinical stage company focused on developing cancer therapeutics, Rekha led finance, investor relations, corporate communications, business and corporate development, strategic planning and human resources. Previously as COO of FLX Bio, a venture funded immune-oncology company, Rekha was responsible for corporate strategy, corporate development, finance, investor & public relations, corporate communications, strategic marketing and G&A operations including legal, facilities and IT. Following the spin-off of FLX from its predecessor company, she has helped FLX restructure and rebuild the product portfolio, grow the company from ~35 to ~65 employees and lead the company through multiple rounds of financing raising > $140 M in private capital.
Previously, in various roles, Rekha has helped companies prepare for and execute IPOs, corporate communication and investor relations strategies, in- and out-licensing of products, mergers & acquisitions and portfolio prioritization. Rekha has experience in the therapeutic areas of oncology, immunology, metabolic diseases as well as endocrinology.
Rekha holds an MBA from the Kellogg School of Management at Northwestern University and a Bachelor of Science from University of Michigan. She serves on the Board of Directors of Hemmo Pharmaceuticals, Pvt Ltd, Mumbai, India, on the Investment Advisory Board of University of Michigan’s Monroe-Brown Seed Fund in Ann Arbor, Michigan as well as on the Board of Regents of Junipero Serra High School in San Mateo, California.
Tuesday, January 28, 2020
2:30 PM – 3:45 PM